GlassScriptPhysician profile
Edith L Gazo
NPI 1629211479
$15,453.58
in general payments reported to CMS, 2019-2025
32 companies · $2,757 in 2025
The $2,757 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,401 · 2022: $3,187 · 2023: $2,858 · 2024: $3,252 · 2025: $2,757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,825 · Education: $40.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,825.43 |
| Education | $40.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,081.23 | 2021-2025 | |
| Amgen INC. | $3,749.22 | 2021-2025 | Enbrel, Avsola, Amjevita |
| Ucb, INC. | $1,547.90 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $1,338.28 | 2021-2025 | |
| Lilly USA, LLC | $1,240.94 | 2021-2025 | Taltz, Zepbound |
| Janssen Biotech, INC. | $481.33 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $440.24 | 2021-2025 | |
| Glaxosmithkline, LLC. | $383.33 | 2021-2025 | Benlysta |
| Radius Health, INC. | $265.41 | 2021-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $251.29 | 2021-2025 | Orencia |
| Alexion Pharmaceuticals, INC. | $219.26 | 2021-2025 | Strensiq, Ultomiris |
| Organon LLC | $172.41 | 2022-2025 | Hadlima, Renflexis |
| Genentech USA, INC. | $140.95 | 2021-2023 | Actemra, Rituxan |
| Fresenius Kabi USA, LLC | $131.11 | 2023-2025 | Idacio, Tyenne |
| Genzyme Corporation | $117.78 | 2021-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $113.46 | 2021-2025 | Acthar |
| Actelion Pharmaceuticals US, INC. | $109.39 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Astrazeneca Pharmaceuticals LP | $102.16 | 2021-2025 | |
| Ferring Pharmaceuticals INC. | $90.78 | 2022-2023 | Euflexxa |
| Sandoz INC. | $72.77 | 2023-2024 | Hyrimoz |
| Horizon Therapeutics Plc | $60.71 | 2021-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $58.12 | 2021-2025 | Lupkynis |
| Kyowa Kirin, INC. | $54.82 | 2024-2025 | Crysvita |
| Ani Pharmaceuticals, INC. | $43.32 | 2024 | Purified Cortrophin Gel |
| Celltrion USA INC. | $40.42 | 2023 | Yuflyma |
| Kiniksa Pharmaceuticals, LTD. | $26.79 | 2022 | |
| Zimmer Biomet Holdings, INC. | $26.62 | 2023 | Allograft |
| Pacira Therapeutics, INC. | $21.33 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.15 | 2024 | |
| Scilex Pharmaceuticals INC. | $17.47 | 2024 | |
| Oxford Immunotec USA INC | $17.15 | 2021 | |
| Fidia Pharma USA INC. | $16.44 | 2025 | Hymovis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edith Gazo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.